scholarly journals Quantifying the effects of mechanical signals on musculoskeletal quality in a model of complete estrogen deprivation

2018 ◽  
Vol 1 (1) ◽  
Author(s):  
Reid Wilson ◽  
Gabriel M. Pagnotti, PhD ◽  
Khalid S. Mohammad, MD, PhD ◽  
Theresa A. Guise, MD
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Bone Loss ◽  
Cancer Patients ◽  
Cortical Thickness ◽  
Bone Area ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Estrogen Deprivation ◽  
Mechanical Signals

Background and Hypothesis:  Post-menopausal, estrogen-receptor positive breast cancer patients are treated with aromatase inhibitors (AIs) to limit tumor progression; however, this causes adverse musculoskeletal effects. Zoledronic acid (ZA) is prescribed to inhibit bone resorption. Mechanical signals, delivered via low intensity vibration (LIV), stimulate bone formation. We hypothesize that combining LIV with ZA will mitigate bone loss in a murine model of complete estrogen-deprivation more effectively than either treatment alone.  Project Methods:  21-week-old C57BL/6 mice (n=20/group) were ovariectomized, receiving daily letrozole injections (OVX/AI) with LIV (OVX/AI+LIV), ZA (OVX/AI+ZA), LIV and ZA (OVX/AI+LIV/ZA) or underwent sham surgery with daily PBS (vehicle) injections (SH-OVX) for 22 weeks. Longitudinal dual energy X-ray absorptiometry (DEXA) and micro-computed tomography scans were analyzed for changes in body composition and bone microarchitecture, respectively.  Results:  OVX/AI reduced whole body (p< 0.0001) and lumbar spine (p<0.0001) bone mineral density (BMD) as compared to SH-OVX by 11% and 28%, respectively, as measured via DEXA. At 22w, OVX/AI+LIV/ZA had greater BMD across both regions-of-interest relative to OVX/AI (p<0.0001). Cortical bone area fraction (p<0.0001) and cortical thickness (p[Symbol]0.001) in distal femora decreased by 8% and 9%, respectively, in OVX/AI relative to SH-OVX. In OVX/AI+LIV/ZA, these parameters were greater relative to OVX/AI (p[Symbol]0.0001). OVX/AI+ZA and OVX/AI+LIV groups were not significantly different from OVX/AI in either cortical bone area fraction or cortical thickness.  Conclusion and Potential Impact:  Complete estrogen-deprivation reduced bone mineral density and altered microarchitecture. Mechanical signals provided via LIV combined with ZA prevent bone loss in aged estrogen-deprived mice. Combining these treatment strategies may reduce skeletal morbidity in breast cancer patients.

Five-year follow-up results of aerobic and circuit training on bone mineral density in early breast cancer patients

2020 ◽  
Vol 138 ◽  
pp. S81
Author(s):  
C. Blomqvist ◽  
L. Vehmanen ◽  
H. Sievänen ◽  
P. Kellokumpu-Lehtinen ◽  
R. Nikander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Circuit Training

scholarly journals Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

1997 ◽  
Vol 75 (4) ◽  
pp. 602-605 ◽  
Author(s):  
T Saarto ◽  
C Blomqvist ◽  
M Välimäki ◽  
P Mäkelä ◽  
S Sarna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Post Menopausal

scholarly journals Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial

2012 ◽  
Vol 138 (9) ◽  
pp. 1569-1577 ◽  
Author(s):  
Christos Markopoulos ◽  
Evagelos Tzoracoleftherakis ◽  
Dimitrios Koukouras ◽  
Basileios Venizelos ◽  
Vasilios Zobolas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Clinical Trial ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Age Effect ◽  
Prospective Clinical Trial ◽  
Breast Cancer Patients ◽  
Mineral Density

10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 676-676 ◽  
Author(s):  
T. Saarto ◽  
L. Vehmanen ◽  
C. Blomqvist ◽  
I. Elomaa
Keyword(s):  
Breast Cancer ◽  
Bone Loss ◽  
Postmenopausal Women ◽  
Cancer Patients ◽  
Early Stage ◽  
Statistical Significance ◽  
Lumbar Vertebrae ◽  
Breast Cancer Patients ◽  
Mineral Density

676 Background: We have previously reported that clodronate prevents bone loss in breast cancer patients (JCO 1997;15:1341, BJC 1997;75(4):602 and EJC 2001;37:2373). Here we report the 10-year follow-up data. Methods: 268 pre- (PRE) and postmenopausal (POST) node positive breast cancer patients were randomized to clodronate (CL), orally 1.6 g daily, or control groups for 3 years. PRE were treated with adjuvant chemotherapy and POST with antiestrogens (AE), tamoxifen 20 mg or toremifene 60 mg, for 3 years. The BMD of the lumbar vertebrae L1–4 (BMDLS) and femoral neck (BMDFN) was measured before the treatment and at 1, 2, 3, 5 and 10 years. 93 patients were eligible for 10-year analyses: 53 PRE and 40 POST. 132 patients had metastatic disease or died and 39 were either lost to follow-up or had to be excluded because having diseases or medications that influences bone metabolism. Results: PRE: BMDLS decreased -12.4% in the control and −8.7% in the CL group in 10 years: from 0 to 3 years −6.9 % vs. −4.2% and from 3 to 10 years −5.5% and −4.5%, respectively. BMDFN decreased −8.8% and −7.2%: from 0 to 3 years −2.9% vs. −2.6% and from 3 to 10 years −5.9% vs. −4.6%, respectively. POST: BMDLS decreased −3.0% in the AE and −1.7% in the AE+CL group in 10 years: from 0 to 3 years −1.5% vs. + 1.2% and from 3 to 10 years −1.5% vs. −2.9%, respectively. BMDFN decreased −7.7% and −6.0%: from 0 to 3 years −0.1% vs. +1.9% and from 3 to 10 years −7.6% vs. −7.9%, respectively. These differences do not reach statistical significance. At 10-years 18 patients had osteoporosis in LS and 15 in FN. Only 4 patients who had osteoporosis at 10 years had normal BMD before the therapy. Conclusions: As reported previously, clodronate prevents the bone loss during treatment in pre- and postmenopausal women. This beneficial effect seems to be maintained at least for 7 years after treatment termination in premenopausal. In postmenopausal women the effect seems to diminish within time. Due to small numbers of patients these differences are no longer statistically significant. Patients at risk of developing osteoporosis are among those who has pretreatment osteopenia i.e. baseline BMD measurement has predictive value. No significant financial relationships to disclose.

scholarly journals Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Karina Monroy-Cisneros ◽  
Julián Esparza-Romero ◽  
Mauro E. Valencia ◽  
Alfonso G. Guevara-Torres ◽  
Rosa O. Méndez-Estrada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Treatment Effect ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Antineoplastic Treatment

scholarly journals Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients

2013 ◽  
Vol 19 (4) ◽  
pp. 431-434
Author(s):  
Soley Bayraktar ◽  
Tiffany Avery ◽  
Kadri Altundag ◽  
Kristine Broglio ◽  
Banu K. Arun
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Cancer Patients ◽  
Bone Mineral ◽  
Postmenopausal Breast Cancer ◽  
Tumor Characteristics ◽  
Breast Cancer Patients ◽  
Mineral Density

scholarly journals Bisphosphonates and the prevention of osteoporosis in the adjuvant setting

2005 ◽  
Vol 8 (11) ◽  
Author(s):  
Michael Gnant
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Loss ◽  
Bisphosphonate Treatment ◽  
Breast Cancer Patients ◽  
Adjuvant Setting ◽  
Mineral Density ◽  
Prevention Of Osteoporosis

Endocrine adjuvant therapy for breast cancer has been associated with a decrease in bone mineral density (BMD) and bone loss. For aromatase inhibitors, this bone loss is likely to be the most significant limitation to their long-term use. Treatments traditionally used to counteract his effect include exercise and supplementation with calcium and vitamin D. A newer treatment is the use of bisphosphonates, a class of drugs that reduce osteoclast activity. Clinical trials currently underway to examine the effect of bisphosphonate treatment on breast cancer patients have shown improvement in bone strength. Additional benefits of bisphosphonates, currently under study, give this class of drugs an important role to play in the treatment of cancer treatment-induced bone loss.

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.

1997 ◽  
Vol 15 (4) ◽  
pp. 1341-1347 ◽  
Author(s):  
T Saarto ◽  
C Blomqvist ◽  
M Välimäki ◽  
P Mäkelä ◽  
S Sarna ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Femoral Neck ◽  
Cancer Patients ◽  
Skeletal Metastases ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Premenopausal Breast Cancer

PURPOSE In the majority of premenopausal breast cancer patients, an adjuvant chemotherapy-induced early menopause occurs, which is known to be a strong predictor of osteoporosis. We present data on the effect of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) therapy on bone mineral density (BMD) and the efficacy of clodronate on the prevention of bone loss in 148 premenopausal breast cancer patients without skeletal metastases. MATERIALS AND METHODS Patients were randomized to receive oral clodronate 1,600 mg/d or to a control group. In addition, patients were treated with six cycles of CMF therapy. BMD of the lumbar spine and femoral neck was measured by dual-energy x-ray absorptiometry (DEXA) before therapy and at 1 and 2 years. RESULTS Changes in the BMD of lumbar spine and femoral neck were -5.9% and -2.0% without clodronate and -2.2% and +0.9% with clodronate at 2 years (P = .0005 and .017, respectively). Patients who developed amenorrhea after chemotherapy had a rapid bone loss, which was significantly reduced by clodronate. In controls, bone loss was 9.5% in the lumbar spine and 4.6% in the femoral neck, while in the clodronate group, bone loss was 5.9% and 0.4%, respectively, at 2 years. Patients with preserved menstruation had only marginal changes in BMD. CONCLUSION Chemotherapy-induced ovarian failure causes rapid bone loss in premenopausal breast cancer patients. Women older than 40 years are at particularly high risk. Clodronate significantly reduces this bone loss.

Sign in / Sign up

Export Citation Format

Share Document